INOVIO PHARMACEUTICALS, INC. (INO): restructuring charge — Inovio cuts 11% of workforce, expects $4.3M annual savings; securities class action settled for $44M

INOVIO PHARMACEUTICALS, INC.

Reduced headcount by 24 employees (11% of full-time staff); one-time charge of $1.1M in Q1 2023.
Expected annual savings of ~$4.3M from reorganization and prior program discontinuations.
Court granted final approval of $44M securities class action settlement: $30M cash (paid by insurers) plus $14M in stock (initially 7M shares; <5% of outstanding).
Key data readouts expected Q1 2023 for INO-3107 (RRP) and VGX-3100 (cervical HSIL) trials.
Restructuring redirects resources to lead DNA medicine candidates; 2022 Q4 results planned for March 2023.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

INOVIO PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $1.1 million (approximately 24 employees).

Type: restructuring
Charge: approximately $1.1 million
Headcount: approximately 24 employees

Exact text from the filing

On January 31, 2023, Inovio Pharmaceuticals, Inc. (the “ Company ”) committed to and communicated a corporate reorganization plan, including a reduction in force (the “ Reduction ”). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company has reduced its overall headcount by approximately 24 employees, which represents 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. The Company expects to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction

View on SEC.gov

Browse all restructurings & charges →

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-019738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.